Please ensure Javascript is enabled for purposes of website accessibility

Here's Why CRISPR Therapeutics Shares Jumped 13.8% in June

By Brian Orelli, PhD – Updated Jul 8, 2020 at 1:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A pair of scientific presentations have investors more confident in the biotech's pipeline.

What happened

Shares of CRISPR Therapeutics (CRSP 1.33%) jumped 13.8% in June, according to data provided by S&P Global Market Intelligence, after the biotech released data at two different medical meetings during the month.

So what

First, CRISPR and its partner Vertex Pharmaceuticals (VRTX -1.11%) presented additional data from its clinical trials testing their gene-editing therapy CTX001 in patients with transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease.

Both patients with TDT haven't required transfusions since they received their therapies five and 15 months ago. That's pretty impressive, considering they previously required 61 units and 34 units of red blood cells per year, respectively, in the two years before treatment.

Nine months after the treatment, the patient with sickle cell disease continues to express fetal hemoglobin, the gene put into the patient via CRISPR-Cas9. The patient remains free of vaso-occlusive crises (VOCs), the painful attacks caused by sickled red blood cells clogging small blood vessels. In the two years prior to treatment, the patient experienced an average of seven VOCs per year.

Doctor talking to a patient

Image source: Getty Images.

Later in June, CRISPR Therapeutics presented data on its CAR-T cell cancer treatment at the American Association for Cancer Research Virtual Meeting II. CRISPR's technology can generate off-the-shelf CAR-T cells made from donor cells rather than needing to be manufactured specifically for each patient like first-generation CAR-T therapies.

Now what

CRISPR Therapeutics is off to a good start in both hematologic diseases and cancer treatments, but investors should keep in mind that the therapies are still early in the clinical-trial marathon, and a lot can happen to derail the treatments before they reach the market.

Given the risks, investors would be wise to keep CRISPR Therapeutics (and any other early-stage biotech) as a small fraction of their overall portfolio.

Brian Orelli, PhD has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends CRISPR Therapeutics. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
$65.35 (1.33%) $0.86
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$289.54 (-1.11%) $-3.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.